Aurobindo obtains FDA nod for generic Onglyza
Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in multiple clinical settings.
Aurobindo has received the Food and Drug Administration’s blessing for Saxagliptin tablets, 2.5 mg and 5 mg, which is the generic version of AstraZeneca’s Onglyza.
Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus in multiple clinical settings.
[Read more: Aurobindo receives FDA approval for 3 generics]
Saxagliptin tablets have a market value of roughly $104.7 million for the 12 months ending May 2023, as per IQVIA.
[Read more: Aurobindo receives FDA approval for 3 generics]